Alpha Teknova (TKNO) Stock Forecast: StockMap's 2-Week Call

TKNO stock forecast: StockMap's model leans Outperform on Alpha Teknova for the two weeks after the Nov 19 close, toward TKNO doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 1 of 3 two-week windows on TKNO since Oct 8; by chance, a call on the same dates was right 61% of the time.

Alpha Teknova last closed at $7.81, -0.89% on the session.

Against the IVW growth benchmark the position is +1.44% over the forecast window.

Alpha Teknova's market cap is $491.26M as of November 19, 2026.

Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 42 (too close to call).

Where TKNO sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 47%.

21 daily calls for TKNO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Alpha Teknova in the 25th percentile on return on equity, where 100 is best.

Alpha Teknova is classified under Health Care / Life Sciences Tools & Services.

StockMap tracks Alpha Teknova as the 36th largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 23 Neutral, 16 Moderate Outperform and 3 Moderate Underperform.

On that composite Alpha Teknova ranks 2nd of 42 in the group, against a group median of +0.13.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Alpha Teknova (TKNO) — StockMap 2-week forecast & tracked accuracy